Clinical Trials Logo

Stage II-III Gastric Cancer clinical trials

View clinical trials related to Stage II-III Gastric Cancer.

Filter by:
  • None
  • Page 1

NCT ID: NCT06157216 Recruiting - Clinical trials for Stage II-III Gastric Cancer

Minimal Residual Disease-guided Adjuvant Therapy for Gastric Cancer

Start date: October 1, 2023
Phase: N/A
Study type: Interventional

This is a multicenter, single-arm, interventional study to explore the feasibility of circulating tumor DNA (ctDNA)-MRD testing to guide postoperative adjuvant treatment strategies in patients with stage II-III gastric cancer.

NCT ID: NCT03403296 Completed - Clinical trials for Stage II-III Gastric Cancer

A Validation Study of Relationships Among Genomic Gene Expression Profile, Prognosis and Prediction of Adjuvant Chemotherapy Benefit With Capecitabine and Oxaliplatin in Gastric Cancer Stage II and III (6th AJCC) Patients After D2 Surgery (CLASSIC)

Start date: July 13, 2016
Phase: N/A
Study type: Observational

The purpose of this study is to validate a pre-defined single-patient classifier algorithm for predicting prognosis and benefit from adjuvant chemotherapy for patients who underwent D2 gastrectomy for stage II and III gastric cancer. This algorithm classifies gastric cancer into five groups according to its molecular characteristics based on RNA expression levels. The prognosis and response from adjuvant chemotherapy will be different according to prognostic and predictive clusters respectively based on these groups, thus this algorithm can identify as patients which will have benefit from adjuvant chemotherapy or which will not. Consequently, this algorithm can be translated into clinical practice to help doctors who decide the necessity of adjuvant chemotherapy after D2 gastrectomy for patients who had diagnosed stage II and III gastric cancer.